MNC Pharma Stocks and Companies in India

The largest MNC Pharma stocks in India by market value are Abbott India (₹57,630 crore), Glaxosmithkline Pharmaceuticals (₹42,890 crore) and Pfizer (₹17,655 crore), at prices of 4 Nov 2026.

• Abbott India: ₹27,120 | market value ₹57,630 crore | P/E 35.7
• Glaxosmithkline Pharmaceuticals: ₹2,531.80 | market value ₹42,890 crore | P/E 40.7
• Pfizer: ₹3,687.80 | market value ₹17,655 crore | P/E 22.2
• Astrazeneca Pharma India: ₹6,368 | market value ₹15,920 crore | P/E 91.7
• Procter & Gamble Health: ₹5,738 | market value ₹9,525 crore | P/E 28.5
• Sanofi Consumer Healthcare India: ₹3,442.30 | market value ₹7,925 crore | P/E 28.3
• Sanofi India: ₹3,204.10 | market value ₹7,775 crore | P/E 21.3
• Novartis India: ₹1,722.40 (close of 3 Nov 2026) | market value ₹4,253 crore | P/E 43.5

Share price | market value | P/E, biggest first. Prices, market values and ratios at the official close of 4 Nov 2026; the score list below uses the weekly figures.

Ranked by the 4-Factor Sector Score (growth & earnings 35, capital efficiency 25, valuation 20, relative strength 20). Prices as of 30 Oct 2026.

All 8 listed Indian Pharma - MNC bulk Drugs companies are named here, largest first. This is the set of companies people mean when they search for a Nifty Pharma - MNC bulk Drugs index; NSE publishes its own indices only for the largest sectors, so this equal-weighted set stands in for one. One large company cannot set the reading.

1. Abbott India Ltd₹54,500 cr
2. Glaxosmithkline Pharmaceuticals Ltd₹42,300 cr
3. Pfizer Ltd₹17,700 cr
4. Astrazeneca Pharma India Ltd₹15,900 cr
5. Procter & Gamble Health Ltd₹9,410 cr
6. Sanofi Consumer Healthcare India Ltd₹7,930 cr
7. Sanofi India Ltd₹7,780 cr
8. Novartis India Ltd₹4,180 cr

8 MNC Pharma companies in the Pharma - MNC bulk Drugs industry group have a page on Sector Alpha, by market value as of 30 October 2026, and all 8 are listed below, largest first. The largest is Abbott India (₹54,474 crore) and the smallest with a market value is Novartis India.

Download all 8 MNC Pharma companies (CSV)

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the last two years (104 weeks) this sector is 4% behind NIFTY 500. Earnings across its companies grew 16% on average over the last four reported quarters.

0 of 8 companies pass the momentum test (5+ points ahead of the Nifty 500 over 3 months, within 20% of the 52-week high). 1 is 20% or more behind over a year while earnings grew 20% or more.

Not ahead of NIFTY 500 on the three-month view this week; 2 of the 8 companies in the industry index above their 200-day average (1 fewer than four weeks earlier); 0 of those 8 pass the momentum test (2 fewer than four weeks earlier); earnings rising at 5 of the 8 that report earnings.

Not ahead of NIFTY 500, not building participation, not giving any back. Earnings mixed, 5 of 8 members have higher trailing twelve-month earnings than a year ago.

Both lines start at 200 in the same week, so the gap between them tells the story: the sector line is an equal-weighted index of its 8 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member set to 100 at the start and the sector taking the middle value, so a price line pulling away from flat bars means the market is paying more for the same earnings. A bar turns grey when that figure is lower than the quarter before. The rules are fixed and the same everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover or tap any point to read both values and the gap.

Pharma - MNC bulk Drugs has done better than the NIFTY 500 by 0.4% over the last 52 weeks. Over 13 weeks the gap is a shortfall of 2.9%. Novartis India Ltd is the strongest against the sector itself at +40.3%.

Pharma - MNC bulk Drugs has done better than the NIFTY 500 by 0.4% over 52 weeks, but is 2.9% behind over the last 13 weeks. 0 of 8 companies we track are beating the NIFTY on relative strength (how a share price has done against the index over recent months), and 2 of the 5 with a long enough price history are ahead of the industry itself.

A score that ranks each company against the others in its industry. The four parts shown always add up to the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or old evidence affects only its own part, never as a hidden adjustment.

Procter & Gamble Health Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 80.6% evidence confidence.

Pfizer Ltd scores well on valuation against its peers or its own history, but its earnings have not yet improved enough to back that up.

Novartis India Ltd has the strongest one-year price move in Pharma - MNC bulk Drugs at +95.1%. It also leads on relative strength against the NIFTY, at +41.9%. 3 of 8 companies we track are ahead of the index on that measure. Every line covers 313 weekly closes through 30 October 2026.

Price and relative strength

Price · same starting point: Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts: the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

RS vs NIFTY 500: How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.

RS vs sector: The same measure taken against Pharma - MNC bulk Drugs itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.

Biggest one-year moves

Strongest against NIFTY 500

Strongest against the sector itself

2 of 8 Pharma - MNC bulk Drugs companies held a results call for April to June 2026. Sanofi India guided: Diabetes: H2 execution to continue across public-sector access, patient support and technology, with no growth rate committed.

From the results calls for April to June 2026.

Big funds, foreign and Indian, kept their stake about the same over the last two quarters. Founders and promoters kept theirs about the same.

• Spending on new plants and equipment was ₹1,387 crore in the last 12 months, 165% more than a year before.
• Projects still being built grew 33% in a year.

Big funds = foreign and Indian institutions, change in their share of ownership across 8 Pharma - MNC bulk Drugs companies, in percentage points.

Ownership and spending as of 10 October 2026.

This is the written read behind the Pharma - MNC bulk Drugs figures above: what is actually happening in the industry, in words, with the evidence each claim rests on. It is dated 28 Jul 2026, so the words are older than the numbers. 4 themes are live here.

The Pharma - MNC bulk Drugs sector shows limited data coverage this week with only 1 constituent, NOVARTIND, reporting results. The demand environment is classified as DETERIORATING based on management commentary. Revenue from operations rose 7.9 percent to Rupees 90.5 crore. The pharmaceutical company recorded improved sales momentum during the quarter.

How old this read is: OLD: this read comes from our Pharma - MNC bulk Drugs sector brief dated 28 Jul 2026, about 3 months ago. The page says so rather than dressing it up, and a fresh sector dive replaces it the day it runs.

What is live in this sector right now

Sources: our Pharma - MNC bulk Drugs sector brief, 28 Jul 2026.

Abbott India Ltd has the highest Revenue among the 8 Pharma - MNC bulk Drugs companies compared here, at ₹7,005 crore. Glaxosmithkline Pharmaceuticals Ltd is next at ₹3,954 crore. Astrazeneca Pharma India Ltd has the highest Revenue growth at 31.2%, so level and change sit with different companies. Its Revenue series carries 19 reported observations across the 20-quarter window.

What the numbers say: Abbott India Ltd is the largest at ₹7,005 crore, 77.2% ahead of Glaxosmithkline Pharmaceuticals Ltd. Astrazeneca Pharma India Ltd's growth is 31.2% from a ₹2,433 crore base, with 19 reported quarters out of the last 20. Fast growth from a smaller base is not yet the same as proven size.

What this means: Abbott India Ltd is the size to compare against; Astrazeneca Pharma India Ltd is the one growing fastest. The faster grower has to keep that growth and turn it into margin and returns before it counts as more than a fast start.

This conclusion weakens if: Abbott India Ltd's growth falls below Astrazeneca Pharma India Ltd's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

Revenue · company comparison

Revenue · largest

Revenue growth · fastest growers

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Revenue shows both size and speed. A large company can absorb shocks and pay for wide distribution; faster growth can mean market-share gains, new capacity or stronger demand. The best sign is usually growth that lasts without hurting margins and returns.

Sanofi Consumer Healthcare India Ltd has the highest OPM among the 8 Pharma - MNC bulk Drugs companies compared here, at 39%. Pfizer Ltd is next at 36%. Sanofi India Ltd has the highest Margin change at +5 percentage points, so level and change sit with different companies. Its OPM series carries 14 reported observations across the 20-quarter window.

What the numbers say: Sanofi Consumer Healthcare India Ltd leads opm at 39%; Sanofi India Ltd leads margin change at +5 percentage points.

What this means: Sanofi Consumer Healthcare India Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

Operating margin · company comparison

OPM · highest

Margin change · fastest expanders

All-company data · latest reported quarter

Abbott India Ltd has the highest Net profit among the 8 Pharma - MNC bulk Drugs companies compared here, at ₹1,615 crore. Glaxosmithkline Pharmaceuticals Ltd is next at ₹1,068 crore. Sanofi Consumer Healthcare India Ltd has the highest Profit growth at 28.4%, so level and change sit with different companies.

What the numbers say: Abbott India Ltd earns the most, ₹1,615 crore of profit over the last 12 months, 51.2% above Glaxosmithkline Pharmaceuticals Ltd. Sanofi Consumer Healthcare India Ltd shows 28.4% growth from a profit base of ₹280 crore. A fast rate from a small base matters less than a large profit that keeps coming.

What this means: Abbott India Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

Net profit · company comparison

Net profit · largest

Profit growth · fastest growers

All-company data · latest reported quarter

Sanofi Consumer Healthcare India Ltd has the highest ROCE among the 8 Pharma - MNC bulk Drugs companies compared here, at 89.9%. Procter & Gamble Health Ltd is next at 83.9%. Procter & Gamble Health Ltd has the highest ROCE change at +27.8 percentage points, so level and change sit with different companies.

What the numbers say: Sanofi Consumer Healthcare India Ltd leads ROCE at 89.9%, 6 percentage points above Procter & Gamble Health Ltd. A high return reported once may be one good year; a high return reported year after year shows a lasting business.

What this means: Sanofi Consumer Healthcare India Ltd sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

Return on capital · company comparison

ROCE · highest

ROCE change · fastest improvers

All-company data · latest reported quarter

Sanofi Consumer Healthcare India Ltd has the lowest PEG among the 8 Pharma - MNC bulk Drugs companies compared here, at 1.07×. Procter & Gamble Health Ltd is next at 1.23×. Sanofi India Ltd has the lowest P/E at 21.3×, so level and change sit with different companies.

What the numbers say: Sanofi Consumer Healthcare India Ltd has the lowest comparable PEG at 1.07×, 13% below Procter & Gamble Health Ltd. That would need today's multiple, the company's own history and steady growth to agree.

What this means: A low valuation is a reason to look closer at the business, not a conclusion on its own.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is worked out the same way every time, as the P/E on the last 12 months of reported earnings divided by that growth rate, never on expected earnings. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

Valuation · company comparison

PEG · lowest PEG

P/E · lowest P/E

All-company data · latest reported quarter

Pharma - MNC bulk Drugs companies show up on 4 of our India lists. The most are on the pharma stocks list (8 companies).

This Pharma - MNC bulk Drugs comparison names 4 specific ways its own evidence can mislead, all listed below. All 8 companies here report on comparable dates, so no rank carries a stale marker. A high growth rate can still come from a very small starting figure.

Keep these limits visible

• A high growth rate can come from a very small starting figure. The page keeps level and change separate for that reason.
• A high ROCE can be temporary, or look high because the capital base is small. It is best read beside margin, cash flow and how much is spent back on the business.
• The 4-Factor Sector Score ranks published data only. Management quality, upcoming events and risks are not part of it.
• An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.

This comparison is built from the reported filings of 8 Pharma - MNC bulk Drugs companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Sep 2026 and market data through 30 October 2026.

Every company's second-feed figures reconcile against the primary source on overlapping reported periods, so nothing here is unverified or withheld.

These 24 answers restate the Pharma - MNC bulk Drugs comparison above in question form. Every one is computed from the same 8 companies and the same reported filings as the rankings and charts, current through Sep 2026. Price and relative-strength answers run through 30 October 2026. Nothing here is estimated, and none of it is a recommendation.